莱斯康制药宣布向美国FDA提交支持Zynquista®在1型糖尿病治疗中效益风险概况的额外数据
莱斯康制药宣布向美国FDA提交支持Zynquista®在1型糖尿病治疗中效益风险概况的额外数据
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.